SCHEMBL41746

SCHEMBL41746

COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCC1CCNC1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 12/20 0.67
RET P07949 4/20 0.67
PDGFRB P09619 2/20 0.67
PLK4 O00444 1/20 0.67
GAK O14976 1/20 0.67
EPHB6 O15197 1/20 0.67
RIPK2 O43353 1/20 0.67
ERN1 O75460 1/20 0.67
STK10 O94804 1/20 0.67
MAP4K4 O95819 1/20 0.67
CHEK2 O96017 1/20 0.67
ABL1 P00519 1/20 0.67
EGFR P00533 1/20 0.67
ERBB2 P04626 1/20 0.67
LCK P06239 1/20 0.67
FYN P06241 1/20 0.67
CSF1R P07333 1/20 0.67
YES1 P07947 1/20 0.67
LYN P07948 1/20 0.67
MET P08581 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4433298 0.95 KDR (0.68) KDRRETPDGFRBPLK4GAK
SCHEMBL1401640 0.88 KDR (0.65) KDRRETPDGFRBPLK4GAK
SCHEMBL6366685 0.86 KDR (0.49) KDRRETPDGFRBPLK4GAK
SCHEMBL16693713 0.84 KDR (0.76) KDRRETPDGFRBPLK4GAK
SCHEMBL15966394 0.84 KDR (0.76) KDRRETPDGFRBPLK4GAK
SCHEMBL665691 0.84 KDR (0.73) KDRRETPDGFRBPLK4GAK
SCHEMBL664923 0.83 KDR (0.63) KDRRETPDGFRBPLK4GAK
SCHEMBL3201243 0.83 KDR (0.73) KDRRETPDGFRBPLK4GAK
SCHEMBL1401711 0.83 KDR (0.75) KDRRETPDGFRBPLK4GAK
SCHEMBL296675 0.83 KDR (0.75) KDRRETPDGFRBPLK4GAK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 314 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2132184-A1 NOVEL PYRIMIDINE DERIVATIVES 698 AstraZeneca AB (SE) 2009-12-16 EP claimed
WO-2008104754-A1 NOVEL PYRIMIDINE DERIVATIVES 698 ASTRAZENECA AB (SE) 2008-09-04 WO claimed
EP-4079735-B1 MACROCYCLIC COMPOUNDS FOR INHIBITING AND INDUCING DEGRADATION OF EGFR KINASE IN THE TREATMENT OF CANCER BEIJING TIDE PHARMACEUTICAL CO LTD (CN) 2025-08-06 EP disclosed
WO-2024092151-A1 DIRECT MEASUREMENT OF ENGINEERED CANCER MUTATIONS AND THEIR TRANSCRIPTIONAL PHENOTYPES IN SINGLE CELLS THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2024-05-02 WO disclosed
WO-2023212293-A1 COMPLEMENT FACTOR H RELATED 4-SPECIFIC ANTIBODIES AND USES THEREOF BROADWING BIO LLC (US) 2023-11-02 WO disclosed
WO-2023212294-A1 ANGIOPOIETIN-RELATED PROTEIN 7-SPECIFIC ANTIBODIES AND USES THEREOF BROADWING BIO LLC (US) 2023-11-02 WO disclosed
WO-2023212298-A1 BISPECIFIC ANTIBODIES AND METHODS OF TREATING OCULAR DISEASE BROADWING BIO LLC (US) 2023-11-02 WO disclosed
EP-4251206-A1 PROTEIN DERIVATIVES CONTAINING UNNATURAL AMINO ACIDS AND BRANCHED LINKERS Brickbio, Inc. (US) 2023-10-04 EP disclosed
WO-2023173170-A1 USE OF 4-THIAZOL-N-(PYRIDIN-2-YL)PYRIMIDIN-2-AMINE DERIVATIVES IN COMBINATION THERAPIES FOR CANCER AUCENTRA THERAPEUTICS PTY LTD (AU) 2023-09-21 WO disclosed
WO-2023173172-A1 USE OF 5-(2-((5-(4-(DIMETHYLAMINO)PIPERIDIN-1-YL)PYRIDIN-2-YL)AMINO)-5-FLUOROPYRIMIDIN-4-YL)-N,4-DIMETHYLTHIAZOL-2-AMINE IN COMBINATION THERAPIES FOR CANCER AUCENTRA THERAPEUTICS PTY LTD (AU) 2023-09-21 WO disclosed
EP-4228702-A1 NON-COVALENT PROTEIN-HYALURONAN CONJUGATES FOR LONG-ACTING OCULAR DELIVERY F. Hoffmann-La Roche AG (CH) 2023-08-23 EP disclosed
WO-2006092574-A1 INDOLYLAMINO QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS ASTRAZENECA AB (SE) 2006-09-08 WO disclosed
WO-2006064217-A2 PROCESS FOR THE PREPARATION OF 4-(6-CHLORO-2, 3-METHYLENEDIOXYANILINO)-7-[2-(4-METHYLPIPERAZIN-l-YL) ETHOXY]-5-TETRAHYDROPYRAN-4-YLOXYQUINAZOLINE , THEIR INTERMEDIATES AND CRYSTALLINE SALTS THEREOF ASTRAZENECA AB (SE) 2006-06-22 WO disclosed
WO-2006051270-A1 5-HETEROARYL THIAZOLES AND THEIR USE AS P13K INHIBITORS ASTRAZENECA AB (SE) 2006-05-18 WO disclosed
WO-2006040522-A1 QUINOLINE DERIVATIVES ASTRAZENECA AB (SE) 2006-04-20 WO disclosed
WO-2006018628-A1 ENANTIOMERS OF SELECTED FUSED PYRIMIDONES AND USES IN THE TREATMENT AND PREVENTI ON OF CANCER ASTRAZENECA AB (SE) 2006-02-23 WO disclosed
WO-2006008523-A1 FUSED PYRIMIDONES USEFUEL IN THE TREATMENT AND THE PREVENTION OF CANCER ASTRAZENECA AB (SE) 2006-01-26 WO disclosed
WO-2006005918-A1 2, 4,6-TRISUBSTITUTED PYRIMIDINES AS PHOSPHOTIDYLINOSITOL (PI) 3-KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2006-01-19 WO disclosed
WO-2006005915-A1 2, 4, 6-TRISUBSTITUTED PYRIMIDINES AS PHOSPHOTIDYLINOSITOL (PI) 3-KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2006-01-19 WO disclosed
WO-2005117888-A1 COMBINATION PRODUCT COMPRISING SRC KINASE INHIBITOR AZDO530 AND AN ANTIOESTROGEN OR EGFR-TK-INHIBITOR ASTRAZENECA AB (SE) 2005-12-15 WO disclosed